Condition
Leukemia, Acute Myeloid (AML), Child
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Terminated2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02065869Phase 1Terminated
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
NCT03733249Phase 1Terminated
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
NCT03301168Phase 1Active Not Recruiting
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Showing all 3 trials